FDA panel to review unexpected viral DNA in Rotarix vaccine
This article was originally published in Scrip
Executive Summary
The US FDA's vaccines and related biological products advisory committee will meet on 7 May to review available data regarding the unexpected finding of DNA originating from porcine circovirus type 1 (PCV-1) in GlaxoSmithKline's Rotarix oral vaccine for rotavirus immunisation.